Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 19/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6237459 | 0.80 | AKR1B1 (0.60) | AKR1B1HTT | |
| SCHEMBL6207325 | 0.73 | AKR1B1 (0.53) | AKR1B1 | |
| SCHEMBL6238851 | 0.72 | AKR1B1 (0.58) | AKR1B1 | |
| SCHEMBL11114753 | 0.70 | SLC6A2 (0.44) | ALDH1A1L3MBTL1 | |
| SCHEMBL11848869 | 0.68 | HTR6 (0.44) | ALDH1A1 | |
| SCHEMBL6206594 | 0.67 | AKR1B1 (0.81) | AKR1B1 | |
| SCHEMBL6206348 | 0.66 | AKR1B1 (0.56) | AKR1B1 | |
| SCHEMBL2478029 | 0.66 | ALDH1A1 (0.63) | AKR1B1ALDH1A1HTTL3MBTL1 | |
| SCHEMBL6761271 | 0.65 | AKR1B1 (0.66) | AKR1B1 | |
| SCHEMBL11846946 | 0.65 | ALDH1A1 (0.44) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1236720-B1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | claimed |
| US-6730674-B2 | ANTIDIABETIC AGENTS | PFIZER INC | 2004-05-04 | — | — | US | claimed |
| US-20030004139-A1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | MARTIN WILLIAM H (US) | 2003-01-02 | — | — | US | claimed |
| EP-1236720-A1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | Pfizer Products Inc. (US) | 2002-09-04 | — | — | EP | claimed |
| EP-1236720-B1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6730674-B2 | ANTIDIABETIC AGENTS | PFIZER INC | 2004-05-04 | — | — | US | disclosed |
| US-20030004139-A1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | MARTIN WILLIAM H (US) | 2003-01-02 | — | — | US | disclosed |
| EP-1236720-A1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | Pfizer Products Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004139-A1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | ALDOA, PDXK, AKR1B1 | AKR1B1 3/4885ALDH1A1 86/4885HTT 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.